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CASE REPORT
First-episode psychosis in a 15 year-old 
female with clinical presentation of anti-NMDA 
receptor encephalitis: a case report and review 
of the literature
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Abstract 
Background: Anti‑NMDA receptor encephalitis is an autoimmune disease that was identified in 2007, and manifests 
in a stepwise manner with psychiatric, neurological and autonomic symptoms. The disease is caused by autoantibod‑
ies against NMDA receptors. It can have a paraneoplastic origin, mainly secondary to ovarian teratomas, but it can also 
be unrelated to the tumor. This disease can affect both sexes and all ages.
Case presentation: Here, we present a case of a 15 year‑old female adolescent with first‑episode psychosis with 
anti‑NMDA receptor encephalitis not related to tumor, which manifested with delusion, hallucinations, panic attacks, 
agitation, and neurological symptoms, and later with autonomic instability. She was treated with immunotherapy and 
psychiatric medication resulting in improvement of her main psychiatric and neurological symptoms.
Conclusion: Our main objective in presenting this case is to alert clinicians to this challenging and recent disease 
that has a clinical presentation that might resemble a functional psychiatric condition and can be underdiagnosed in 
the context of child and adolescent psychiatry.
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Background
Anti N-methyl-d-aspartate (NMDA) receptor encepha-
litis is an autoimmune disease that was initially identi-
fied as paraneoplastic syndrome in young women with 
ovarian teratomas [1]. Although some case reports of 
encephalitis in patients with ovarian teratoma had been 
published since 1997 [2–6], a definitive association 
between anti-NMDA receptor antibodies and encepha-
litis was established by Josep Dalmau and colleagues in 
2007 [7]. Since then, several case reports, case series, 
multicenter studies and other works have been pub-
lished. In addition to medical literature, this disease has 
become known by lay media and the general population. 
In 2012 the New York Post writer Susannah Cahalan 
published an autobiographical book titled Brain on Fire, 
where she described her experience with anti-NMDA 
receptor encephalitis that was dominated by presen-
tation of delusion, hallucinations, and later with neu-
rological symptoms [8]. The clinical presentation of 
anti-NMDA receptors encephalitis includes three main 
stages: (1) an initial period with viral prodrome and com-
mon cold-like symptoms that can last up to 1 week; (2) 
an intermediate stage, that can last from 1 to 3  weeks, 
mainly with psychiatric symptoms such as delusions, 
hallucinations, mania, agitation, changes in speech and 
disorganization (often seizures); and (3) prominent neu-
rological symptoms, such as movement abnormalities, 
dysautonomia, hypoventilation and seizures that can last 
from weeks to months, with possible need for intensive 
care unit support [9]. Anti-NMDA receptor encephali-
tis affects both sexes and has been observed in all ages, 
although it is more frequent in young adults and children 
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with or without teratomas [10, 11]. Exact prevalence of 
this disease is unknown, but according to epidemiologi-
cal studies it is the most common cause of autoimmune 
encephalitis, ranking immediately after acute demyelinat-
ing encephalomyelitis [12]. According to the California 
Encephalitis Project, anti-NMDA receptor encephalitis 
is more frequent than any specific viral encephalitis [13]. 
This disease is fatal if left untreated, but patients improve 
with adequate measures, including intensive care sup-
port, immunotherapy and prolonged hospital stay with 
multidisciplinary care [10, 14]. When there is an under-
lying tumor, such us an ovarian teratoma, the prognosis 
after tumor resection is usually better than in the absence 
of tumor [10]. Recovery is usually slow; can take years, 
and may be associated with prolonged neuropsychiatric 
deficits [15]. Usually, psychiatrists are the first physicians 
to observe these patients because of the prominent pres-
entation of behavioral symptoms, mood changes, and 
psychotic symptoms [10].
Here, we present a case report of a 15 year-old teenager 
with presentation mentioned above, where the diagno-
sis of anti-NMDA receptor encephalitis was considered 
and confirmed by detection of anti-NMDA antibodies in 
spinal fluid and clinical improvement after immunother-
apy. Time between onset of symptoms and diagnosis was 
23  days, which illustrates the difficulties in establishing 
diagnosis of anti-NMDA receptor encephalitis (a pleo-
morphic condition and a relatively new disease), which is 
why clinicians are not well aware of it. We highlight the 
importance of considering timely diagnosis, since it has 
a specific treatment with dramatic effect in the prognosis 
of these patients.
Case presentation
A previously healthy 15  year-old female presented with 
behavioral changes with incoherent speech, restlessness, 
anxiety, and expressed the feeling that “everything is hap-
pening to me” after attending a 2-day spiritual retreat. 
One week before the presentation of psychiatric symp-
toms, she had unspecific common cold symptoms, but 
with no fever. On the second day of psychiatric presen-
tation, she had a transient period of agitation and visual 
hallucination with spontaneous remission (she saw Jesus 
and her deceased grandparents). On the third day, she 
was brought to the emergency room (ER), for the first 
time, owing to an episode of agitation and speech block-
ade that happened at school. Concomitantly, she had 
somatic manifestations, such as swallowing impairment, 
odynophagia for water and food refusal. She showed 
regressive behavior, such as asking for help for basic 
hygiene and refusal to sleep alone. At this point, epi-
sodic speech changes, such as echolalia and verbal per-
severation and intermediary insomnia were documented. 
Of note, there were no changes in the flow of thoughts 
or indication of disorganized behavior. The patient was 
medicated with risperidone (0.5 mg once a day) by the ER 
child and adolescent psychiatry attendant, and referred 
to the Child and Adolescent Psychiatry Outpatient 
Clinic. However, a few hours later, she was re-admitted in 
the pediatric ER with panic symptoms (tachypnea, tachy-
cardia, shaking hands, and sweating). She was discharged 
and medicated with lorazepam (0.5 mg two times a day) 
and risperidone (1 mg once a day) with no improvement, 
namely, the visual hallucination persisted.
At the first child and adolescent psychiatry outpatient 
appointment (day 7 after symptoms onset), she was ori-
ented, and presented with unexpressive facial mim-
icry, provoked speech, and psychomotor retardation. 
No changes in the form, rhythm or flow of thoughts, 
or delusions were documented. The patient had anxi-
ety with no mood changes, although she had a regres-
sive attitude. The patient was medicated with anxiolytics 
(diazepam 5 mg two times a day), and risperidone (1 mg) 
was increased to twice daily. At the next child and ado-
lescent psychiatry appointment (day 10 of the disease), 
she maintained episodes of agitation with tremor of the 
upper limbs, screaming, and a desperation gaze that 
was attributed to hallucinations, according to her fam-
ily. During these episodes, the patient said that “they 
are after me (…) I am a saint (…) nobody will survive…”. 
On other occasions she would experience periods of ela-
tion, with tendency to sing and express grandiose delu-
sions: “I will be the best student at my class”. During the 
mental state examination she was extremely sleepy, calm 
with provoked speech, and answered with monosyllables. 
Therapy was adjusted, and risperidone was replaced with 
olanzapine (10  mg once a day). She was recommended 
for hospital admission, but the patient’s family refused 
this recommendation.
On day 18 of the disease, with no signs of clinical 
improvement, the patient was brought to a new appoint-
ment, and admitted in a psychiatry ward. At admission 
she was oriented to time, place, person and situation but 
showed periods of negativism, mutism, echolalia, echop-
raxia, motor agitation, upper limb tremor (that occurred 
at rest, with sudden onset and remission and disappeared 
when she was distracted), These symptoms occurred in 
bursts alternated with periods of normal speech but with 
pervasive prostration. Also, she was unable to take care 
of her own hygiene. At physical examination she did not 
have fever or changes in blood pressure, and cardiac or 
respiratory frequency. Pulmonary and cardiac ausculta-
tion were unremarkable, abdomen examination was also 
normal, and at the examination she had no changes of the 
skin and upper and lower limbs. At that point, the follow-
ing diagnostic hypotheses were considered: prodromal 
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phase of an affective psychosis, anxiety disorder with 
conversion traits, dissociative disorder (depersonali-
zation disorder), organic disorder, and psychosis with 
catatonic features. Due to the catatonic symptoms, the 
diagnosis of neuroleptic malignant syndrome was also 
raised and a possible treatment with dopamine agonist 
was considered. However, this specific intervention was 
deferred since the patient had no fever or changes in the 
blood pressure, cardiac or respiratory frequency or labo-
ratory imbalance. The diagnostic hypotheses were based 
on the clinical presentation, physical examination, and 
mental state examination. We did not apply the mini-
mental state examination or any other rating scale for 
psychosis, mood, cognitive or neurologic symptoms.
Laboratory results and brain CT scan were normal. 
Psychiatric medication for psychosis was started. At day 
5 after admission (day 23 of clinical disease), a lumbar 
puncture was performed with screening for antibodies 
for anti-NMDA receptors in the spinal fluid. Since the 
hypothesis of anti-NMDA receptors encephalitis was 
raised, it is mandatory to first rule out possible underly-
ing neoplasm. Because the patient was female and ovar-
ian teratoma can occur in up to 59  % of cases [10], a 
pelvic ultrasound was performed, but no changes were 
found. On the same day, the patient experienced tachy-
cardia and decreased consciousness, with the need for 
intensive care unit (ICU) admission. No rating scale was 
applied during the stay in the intensive care unit. How-
ever, antibodies for NMDA receptors were detected 
and diagnosis of anti-NMDA receptor encephalitis was 
established.
At the ICU the patient experienced periods of delu-
sion and agitation with loud screaming. She was medi-
cated with midazolam (2 mg intravenous if needed), oral 
lorazepam (1 mg three times a day), and chloral hydrate 
(1  g every 6  h). Within the first few hours, risperidone 
was introduced at 0.5 mg daily and then titrated to 1 mg 
daily. She was subsequently treated with immunoglobu-
lin (2  mg/kg/day), methylprednisolone (30  mg/kg/day), 
and plasmapheresis and rituximab (375  mg/m2/week). 
Regarding the maintenance psychopharmacology, the 
patient was on risperidone (1  mg two times a day) and 
lorazepam (2.5 mg if needed).
Two months after specific treatment for anti-NMDA 
receptor encephalitis, the patient still had difficulty with 
verbal articulation, but there were no changes regarding 
form, course, rhythm or thought content, and her mood 
was euthymic. She reported periods of emotional lability, 
although less frequent than before treatment, and there 
were no auditory or visual hallucinations. She reported 
moderate verbal memory impairment, attention and con-
centration difficulties at school. Although a formal neu-
ropsychological evaluation was not performed, it was 
known that before disease onset, the patient had no cog-
nitive difficulties at school since her IQ was considered 
within the normal range, and her grades were average. 
She started psychotherapy, physiotherapy, and learning 
support at school. She had progressive clinical improve-
ment but still experienced emotional lability, anxiety, and 
verbal memory impairment, attention and concentra-
tion difficulties at school that justified her enrolment in a 
vocational educational school. Ten months later she had 
a seizure episode and a new treatment cycle was started. 
Since she experienced depressive symptoms after the 
encephalitis episode, sertraline (25  mg once a day) was 
added to her medication regimen. As of this writing, 
she is medicated with oxcarbazepine (450 mg two times 
a day), quetiapine SR (100  mg at bedtime), sertraline 
(25 mg once a day) and lorazepam (1 mg if needed). Also 
as of this writing (almost 3 year after the disease onset), 
the patient’s psychiatric symptoms have improved, but 
she still experiences verbal memory impairment, and 
attention and concentration difficulties.
Discussion
In this present case, it was clear that we were not facing a 
common psychiatric condition. A diagnosis of an organic 
psychiatric disorder was considered because of the pres-
ence of atypical psychiatric symptoms such as visual 
hallucination and also by the uncommon sequence and 
mixture of psychiatric and neurologic symptoms. A diag-
nosis of anti-NMDA receptor encephalitis was hypoth-
esized because of the following course of the illness: 
1  week before symptoms onset the patient experienced 
common cold-like symptoms; day 1 of symptoms onset, 
she experienced incoherent speech, restlessness and 
expressed the feeling that “something was happening”; 
day 2, she presented with visual hallucinations and agita-
tion; day 3, she was agitated, had speech blockade, had 
difficulty swallowing and refused to eat; day 5, she dis-
played panic attack; day 8, she experienced psychomotor 
retardation, speech changes, and regressive posture; day 
10, she displayed agitation, tremor in her upper limbs, 
mood elation, and persecutory and grandiose delusions; 
day 18, she had episodes of negativism, mutism, tremor, 
echopraxia, prostration, and neglected her hygiene. At 
that moment she was admitted into a psychiatry ward. 
Blood workup and brain CT scan were normal. At day 23 
of the disease (5 days after her admission in the psychia-
try ward), a lumbar puncture was performed to test for 
auto-antibodies against NMDA receptors, and owing to 
decreased consciousness and catatonia she was admitted 
to an ICU. This clinical picture is consistent with the sev-
eral cases of anti-NMDA receptor encephalitis that have 
been reported in literature [10, 15–21]. Anti-NMDA 
receptor encephalitis is an autoimmune disease that was 
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first identified as a paraneoplastic syndrome in young 
women with ovarian teratomas, and can also occur as a 
rare manifestation of teratoma of the mediastinum, or 
due to testicular cancer or small-cell lung carcinoma [7, 
10]; however it can also be non-paraneoplastic [3, 22]. 
The clinical presentation usually consists of three stages: 
a prodromal period that lasts up to 1  week with com-
mon cold-like symptoms, fever, headache, malaise or gas-
troenteritis; an intermediate period, lasting 1–3  weeks, 
with behavioral changes, psychiatric symptoms or 
mood changes. The most common clinical presentation 
resembles acute psychosis (anxiety, agitation, paranoia, 
auditory or visual hallucinations) [7, 23], meaning that 
psychiatrists are usually the first physicians to observe 
these patients. The third stage can last from weeks to 
months, and consist of neurological and autonomic 
symptoms, including alteration in speech, catatonia, and 
seizures. The common autonomic symptoms include uri-
nary incontinence or sleep dysfunction. The more severe 
autonomic symptoms, such as hypoventilation, dysrhyth-
mia, tachycardia, and hyperthermia, are not frequent in 
children [11]. It has been shown that this condition is 
more frequent in children than was previously thought 
and that its clinical manifestations in the pediatric popu-
lation are similar to those of adults [11].
The exact pathophysiology of anti-NMDA receptor 
encephalitis is not fully understood. It is believed that 
NR1 subunits expressed by tumoral neural tissues may 
break the immune tolerance [10]. However, anti-NMDA 
receptor encephalitis is not always related to teratoma 
or other malignancies, and hence, other immunologic 
mechanisms might be involved. Hypotheses thus far pro-
posed include the concept that there is an immunological 
response to a flu-like prodromal phase possibly related 
to a viral infection, and genetic susceptibility [10]. It is 
well known that NMDA plays an important role in the 
mechanism of psychosis, which is supported by associa-
tion studies on hypofunction of glutamate and psychosis 
symptoms [24]. Also, immunoglobulin against NR1 can 
induce a reversible hypofunction of the glutamate recep-
tors by triggering internalization of the receptors [25]. In 
our patient, the underlying etiology was unknown, but 
we cannot rule out a possible viral mechanism, since she 
had a short period of common cold-like symptoms before 
symptoms onset, and no tumor was detected.
Regarding the diagnosis, brain imaging is not helpful 
because there are no specific imaging biomarkers associ-
ated with this syndrome, though most patients may show 
minor nonspecific abnormalities during brain imaging 
[10]. For example, an MRI may show cerebral, cerebel-
lar or brainstem hyperintensities [10]. Transient contrast 
enhancements of the cerebral cortex, meninges, and 
basal ganglia have also been noted [10]. Furthermore, 
though not specific, EEG may show epileptiform activ-
ity or diffuse slow waves [10]. The cerebrospinal fluid 
may have pleocytosis, high protein levels, and oligoclonal 
bands. Diagnosis is made on the presence of anti-NMDA 
receptor antibodies in the spinal fluid and/or in the blood 
[10]. Underlying neoplasm should be ruled. Since ovarian 
teratomas are the most frequent tumors associated with 
anti-NMDA receptor encephalitis, at least an ultrasound 
or MRI of the abdomen and pelvis must be considered in 
the initial diagnosis, and periodically for at least 2 years 
after the episode. However, attention should be paid to 
other tumors such as the more frequently associated with 
this autoimmune disorder (e.g. extraovarian teratomas, 
testicular, lung and breast tumors, ovarian carcinoma, 
thymic carcinoma or pancreatic cancer) [15]. Since virtu-
ally all tumor may trigger the production of autoantibod-
ies against NMDA receptors, clinicians should consider 
the assessment of a possible underlying tumor according 
to the signs and symptoms of each clinical case. In our 
patient, the blood chemistry was normal and she had 
no alterations on brain CT. Since she was a 15 year-old 
adolescent, a pelvic ultrasound was performed to rule 
out tumor or teratomas, but no changes were found. 
Lumbar puncture was performed 5 days after her admis-
sion (23  days after disease onset) and was found to be 
positive for anti-NMDA receptor auto-antibody. At that 
time the patient also experienced autonomic instability, 
namely tachycardia, and also more severe neurological 
symptoms, such as decreased consciousness that justified 
her admission to the ICU. These findings in our patient 
were also consistent with the third stage of the course of 
the disease that can culminate in admission to the ICU. 
We further highlight the fact that diagnosis was made 
23 days after symptoms onset. The delay was mainly due 
to the fact that the disease was reported for the first time 
only 10 years ago as of this report, which means that the 
clinicians were not yet aware of this syndrome. Since 
the course of the disease usually presents with psychiat-
ric symptoms, and adult psychiatrists or child psychia-
trists are the first physicians to see the patients, usually 
a preliminary diagnosis of a functional psychosis is made 
and psychopharmacology treatment is started. Indeed, a 
similar scenario happened with our patient, since she was 
admitted to the psychiatric ward after failure to respond 
to antipsychotics and benzodiazepines. However, we 
emphasize the fact that the pleomorphic presentation of 
the disease raised the hypothesis of possible atypical psy-
chiatric conditions.
In terms of treatment for anti-NMDA receptor 
encephalitis, if a neoplasm is detected, tumor removal 
and immunotherapy (corticosteroids, intravenous 
immunoglobulin or plasma exchange) are the first-line 
treatments. In such cases, second-line immunotherapy 
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(cyclophosphamide and/or rituximab) is seldom 
needed. However, in cases unrelated to tumors, first-
line therapy tends to be less efficient, and escalation to 
second-line immunotherapy is frequently necessary [7]. 
Significant improvement occurs in more than two-third 
of patients after 2–3  months of therapy, which corre-
lates with decreasing antibody titers. Symptoms resolu-
tion is inversely proportional to the order of symptom 
development [7]. Our patient was treated with immuno-
globulin (2 mg/kg/day) and methylprednisolone (30 mg/
kg/day), plasmapheresis, rituximab (375  mg/m2/week) 
and risperidone (1 mg two times a day) and lorazepam 
(2.5  mg if needed). Since she had no tumor, her prog-
nosis was worse than if she had a neoplasm. Relapses 
have been documented in literature [10]. Ten months 
after symptoms onset, our patient had a seizure episode 
and a new treatment cycle was started. These findings 
are also consistent with the literature since the long 
course of the disease is characterized by slow recovery 
that can take years, and may be associated with pro-
longed neuropsychiatric deficits [15]. Presently (almost 
3  years after the disease onset), the psychiatric symp-
toms have improved, but she still experiences verbal 
memory impairment, attention and concentration dif-
ficulties. According to the literature, long-lasting cogni-
tive deficits, mainly memory impairment and executive 
dysfunction may occur in about 88.8  % of the patients 
[26]. Although a recent study (using MRI of patients 
after anti-NMDA receptor encephalitis), reported that 
hippocampal volumetric and microstructural impair-
ments correlate with memory performance [27], in our 
patient, we did not perform any further imaging study 
such as MRI.
Regarding the outcome, the main good prognostic 
factors are: early detection and intervention, presence 
and subsequent removal of an underlying tumor, good 
response to first line immunotherapy, no need for inten-
sive care unit admission, and the absence of relapses [10, 
15]. Our patient had more bad than good prognostic fac-
tors since she had no tumor, the diagnostic was made 
23  days after symptoms onset, she experienced auto-
nomic symptoms, she was subsequently admitted to an 
intensive care unit and had a relapse 10 months after the 
symptoms onset.
Finally, we would like to highlight that even though 
anti-NMDA receptor encephalitis is classically described 
as having a step-wise presentation with a prodromal 
flu-like phase followed by periods of psychiatric, neu-
rological and autonomic symptoms, these phases and 
symptoms (mainly the psychiatric and neurological ones) 
can occur in a mixed form as in the case of our patient. 
Such an uncommon presentation of psychiatric and 
neurological symptoms before the autonomic instability 
should raise the clinician awareness to consider a diagno-
sis of an organic psychiatry disorder.
Conclusions
Anti-NMDA receptor encephalitis is a serious and fatal 
disease if left untreated. However, there is no scientific 
support for anti-NMDA receptor encephalitis laboratory 
testing in patients with psychotic symptoms even though 
anti-NMDA receptor encephalitis presenting with psy-
chosis is not a rare disease [10]. The hopeful goal of this 
case report is to raise clinician awareness of anti-NMDA 
receptor encephalitis in psychotic adolescent patients 
with atypical psychiatric presentation and concomitant 
neurological symptoms, such as speech alteration and 
motor changes, even in the absence of malignancies.
Abbreviation
NMDA: N‑methyl‑d‑aspartate.
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